← Back to Search

Aerobic Walking for Parkinson's Disease(LTAE-PD Trial)

University of Iowa Hospitals & Clinics, Iowa City, IA
Aerobic walking +1 morePhase 2 & 3Waitlist AvailableLed by Ergun Y. Uc, MDResearch Sponsored by VA Office of Research and Development

LTAE-PD Trial Summary

This trial will test the long term effects of aerobic exercise on the brain tissue, movement, mental functions, and driving in Parkinson's Disease patients.

Eligible Conditions
  • Parkinson's Disease

LTAE-PD Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
People aged 40 and older diagnosed with Parkinson's disease according to specific criteria.
Select...
You are at a certain stage of Parkinson's disease and have been on the same medication for at least 4 weeks before starting the study.
Select...
Your aerobic fitness level is below what is considered very good for your age and gender during a cycling test.
Select...
You do not have dementia according to specific criteria from the Movement Disorder Society.

LTAE-PD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline vo2max on cycle ergometry at 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline vo2max on cycle ergometry at 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MDS-UPDRS Non-motor Experiences of Daily Living subscale (Part I) score
OFF period MDS-UPDRS Motor Subscale score
Percent Increase Score (PIS) on Eriksen's flanker task
+3 more
Secondary outcome measures
Beck Anxiety Inventory (BAI) score
COGSTAT score
Dexterity (time on 9-hole peg board) test of NIH Toolbox motor battery
+16 more
Other outcome measures
VO2max on cycle ergometry

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

LTAE-PD Trial Design

2Treatment groups
Experimental Treatment
Group I: ControlExperimental Treatment1 Intervention
Participants randomized to usual care with PD specific health education
Group II: AerobicExperimental Treatment1 Intervention
Participants randomized to aerobic exercise

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,583 Previous Clinical Trials
2,897,618 Total Patients Enrolled
University of IowaOTHER
435 Previous Clinical Trials
870,246 Total Patients Enrolled
Ergun Y. Uc, MDPrincipal InvestigatorIowa City VA Health Care System, Iowa City, IA
1 Previous Clinical Trials
104 Total Patients Enrolled

Media Library

Aerobic walking Clinical Trial Eligibility Overview. Trial Name: NCT03808675 — Phase 2 & 3
Parkinson's Disease Research Study Groups: Control, Aerobic
Parkinson's Disease Clinical Trial 2023: Aerobic walking Highlights & Side Effects. Trial Name: NCT03808675 — Phase 2 & 3
Aerobic walking 2023 Treatment Timeline for Medical Study. Trial Name: NCT03808675 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people with the required medical history still able to sign up for this research program?

"Correct, this research is ongoing and is recruiting participants, as stated on the clinicaltrials.gov website. The listing for this trial was first posted on 7/1/2019, and the most recent update was on 8/26/2022."

Answered by AI

Why was this research project undertaken?

"The aim of this study, as evaluated by the change in Baseline Percent Increase Score (PIS) on Eriksen's flanker task over the course of a year, is to improve regional DTI. Additionally, this study will also monitor changes in motor function, ability to complete activities of daily living, and cognitive and memory skills."

Answered by AI

Who else is applying?

What state do they live in?
Utah
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~7 spots leftby Jun 2024